Preclinical target validation using patient-derived cells.

Edwards AM.; Arrowsmith CH.; Bountra C.; Bunnage ME.; Feldmann M.; Knight JC.; Patel DD.; Prinos P.; Taylor MD.; Sundström M.; SGC Open Source Target-Discovery Partnership None.

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Preclinical target validation using patient-derived cells.

Edwards AM., Arrowsmith CH., Bountra C., Bunnage ME., Feldmann M., Knight JC., Patel DD., Prinos P., Taylor MD., Sundström M., SGC Open Source Target-Discovery Partnership None.

The Structural Genomics Consortium (SGC) and its clinical, industry and disease-foundation partners are launching open-source preclinical translational medicine studies.

Original publication

DOI

10.1038/nrd4565

Type

Journal article

Journal

Nat Rev Drug Discov

Publication Date

03/2015

Volume

Pages

149 - 150

Keywords

Cell Line, Drug Evaluation, Preclinical, Humans, Patients, Primary Cell Culture, Public-Private Sector Partnerships, Translational Medical Research